Related Experiment Video
Updated: May 13, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Medical management of venous thromboembolism: what the interventional radiologist needs to know
1Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Insights
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, affects 1-3 per 1000 people. This review discusses VTE risk factors, anticoagulation duration, and emerging oral anticoagulant treatments.
Area of Science:
- Cardiovascular Medicine
- Hematology
Background:
- Deep vein thrombosis and pulmonary embolism are manifestations of venous thromboembolism (VTE).
- VTE affects 1-3 per 1000 individuals, with incidence projected to rise due to increased life expectancy.
- Current VTE treatment relies on anticoagulation, with duration dependent on the thrombotic event's context.
Purpose of the Study:
- To review risk factors associated with VTE.
- To outline the approach for determining anticoagulation duration in VTE patients.
- To discuss clinical trial results of new oral anticoagulants for VTE treatment.
Main Methods:
- Review of existing literature on VTE.
- Analysis of clinical trial data for novel oral anticoagulants.
- Discussion of risk stratification and anticoagulation management strategies.
Main Results:
- Vitamin K antagonists, the current oral standard, have drawbacks.
- New oral anticoagulants are in development and show promise for VTE treatment.
- Determining anticoagulation duration requires careful consideration of individual patient factors.
Conclusions:
- VTE remains a significant health concern with increasing incidence.
- Optimizing anticoagulation duration is crucial for effective VTE management.
- Novel oral anticoagulants may offer improved VTE treatment options.
Abstract:
Deep vein thrombosis and pulmonary embolism are considered manifestations of the same pathophysiological process and are together referred to as venous thromboembolism (VTE). VTE is a common disorder with an incidence of 1 to 3 in 1000 in the general population. It is estimated that the incidence of VTE is likely to increase as the average life expectancy of the U.S. population increases. Treatment of VTE consists of anticoagulation; the duration of anticoagulation is largely determined by the circumstances surrounding development of the thrombotic event. Vitamin K antagonists, the only oral anticoagulants approved for treatment of VTE in the United States, have several drawbacks and therefore new oral anticoagulants are currently in various stages of development. This review focuses on the risk factors for VTE and the approach to determining the duration of anticoagulation in patients with VTE. Results of clinical trials on the new oral anticoagulants that may soon be licensed for the treatment of VTE are also discussed.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
